Conference Coverage: ASCO 2022 – Focus on Genitourinary (GU)

Impact of recent ASCO data on clinical practice and therapy guidance in genitourinary cancer

June 10, 2022

Faculty Chair

Daniel Petrylak, MD

Yale University, New Haven, CT, USA

FACULTY MEMBERS

Emmanuel Antonarakis, MD
University of Minnesota Medical School, Minneapolis, MN, USA

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA

Karim Fizazi, MD, PhD
Institute Gustave Roussy, Villejuif, France

Leonard G. Gomella, MD, FACS
Jefferson University Hospitals, Philadelphia, PA, USA

Thomas Powles, MD, MBBS, MRCP
Barts Cancer Institute, London, UK

Susan Slovin, MD, PhD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Scott Tagawa, MD, MS, FACP
Weill Cornell Medical Center, New York, NY, USA

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Localized and Metastatic Castration-Sensitive Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Advanced Renal Cell Carcinoma
  • Renal Cell Carcinoma – Subgroup-Specific Therapies
  • Novel Therapies for NMIBC and MIBC
  • Novel Therapies for Metastatic Bladder Cancers

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.